TargetCancer Funds Mesothelioma and Other Rare Cancer Research
When Paul Poth, a Boston attorney, was diagnosed with a rare form of cancer at the age of 38 he was dismayed by the lack of resources his physicians had available to them for his treatment. He soon realized that this is the case for many rare cancers, including mesothelioma, and hoping to make a difference he and his family formed TargetCancer. Poth died shortly after founding TargetCancer.
TargetCancer “promotes the development of lifesaving treatment protocols for rare cancers. Through fundraising, outreach, and advocacy, TargetCancer supports those living with rare cancers and funds research initiatives at the forefront of cancer treatment – efforts that treat the individual as well as the disease.” Some of the cancers targeted include hepatobiliary (bile duct) cancer, from which Poth died, esophageal cancer, mesothelioma, certain brain tumors, and others.
Mesothelioma, an unusual form of cancer which can take up to five decades to be properly diagnosed, is responsible for approximately 3,000 new cases each year in the United States. Although there is no cure for mesothelioma, it can be treated with varying degrees of success through the use of surgical procedures, chemotherapy and radiation. Research continues to find a cure for the disease.
In February TargetCancer launched “The Right Track.” This initiative offers a series of concerts, events, and music downloads of which 100 percent of the proceeds will go directly to TargetCancer. The music available on this site is rare and previously unreleased tracks donated by performers. See The Right Track to download songs.
In July 2009, TargetCancer made its first donation to the Center for Molecular Therapeutics at the Massachusetts General Hospital Cancer Center.
Label: For Your Family